Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | KDM5C | P41229 | 2/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29277291 | 0.97 | EGLN1 (0.36) | EGLN1PHF8KDM2AKDM4EKDM5C | |
| SCHEMBL2558809 | 0.82 | HMGCR (0.40) | EGLN1PHF8KDM2AHMGCRCHRM1 | |
| SCHEMBL22694095 | 0.81 | POLB (0.32) | EGLN1PHF8KDM2AKDM4EHMGCR | |
| SCHEMBL93673 | 0.80 | ALDH1A1 (0.35) | EGLN1PHF8KDM2AHMGCRCHRM1 | |
| SCHEMBL15542520 | 0.80 | ALDH1A1 (0.34) | EGLN1PHF8KDM2AKDM4EKDM5C | |
| SCHEMBL23553761 | 0.80 | CTH (0.33) | EGLN1PHF8KDM2AKDM4EKDM5C | |
| SCHEMBL18509319 | 0.80 | CTH (0.38) | EGLN1PHF8KDM2AKDM4EKDM5C | |
| SCHEMBL15197024 | 0.80 | EGLN1 (0.39) | EGLN1PHF8KDM2AKDM4EKDM5C | |
| SCHEMBL5791807 | 0.80 | PKM (0.44) | KDM4ECYP2C19HIF1ALMNAALDH1A1 | |
| SCHEMBL10249976 | 0.79 | MGAM (0.36) | EGLN1PHF8KDM2AKDM4EKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 745 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282819-A1 | MITOCHONDRIA-SPECIFIC PEPTIDE THAT CAN BE INTRACELLULARLY DELIVERED AT NANOMOLAR CONCENTRATION, AND USE THEREOF | CAMP THERAPEUTICS INC. (KR) | 2025-09-11 | — | — | US | claimed |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| WO-2024253439-A1 | COMPOSITIONS FOR PREVENTING OR TREATING OBESITY OR NON-ALCOHOLIC FATTY LIVER DISEASE COMPRISING MITOCHONDRIA-SPECIFIC PEPTIDES | (주) 캠프테라퓨틱스 | 2024-12-12 | — | — | WO | claimed |
| WO-2024167324-A1 | COMPOSITIONS FOR PREVENTING OR TREATING KIDNEY OR LIVER DISEASES COMPRISING MITOCHONDRIA-SPECIFIC PEPTIDES | (주) 캠프테라퓨틱스 | 2024-08-15 | — | — | WO | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| CN-118317971-A | Mitochondrial-specific peptides capable of intracellular delivery at nanomolar concentrations and uses thereof | 坎普疗法有限公司 | 2024-07-09 | — | — | CN | claimed |
| EP-4259120-A1 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-10-18 | — | — | EP | claimed |
| US-20230312653-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2023-10-05 | — | — | US | claimed |
| EP-0780408-A2 | Chiral solid-phase for the chromatographic separation of optical isomers | BAYER AG (DE) | 1997-06-25 | — | — | EP | claimed |
| EP-0584664-A1 | Polymerizable dipeptides: preparation, polymerization and use of polymers for the chromatographic separation of enantiomers | BAYER AG (DE) | 1994-03-02 | — | — | EP | claimed |
| EP-0564972-A2 | Peptides with N-terminal modifications having bradykinin antagonistic activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-10-13 | — | — | EP | claimed |
| EP-0531443-A4 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | — | 1993-04-21 | — | — | EP | claimed |
| EP-0531443-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-03-17 | — | — | EP | claimed |
| US-5079260-A | Side effect reduction; fluorene derivatives | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-01-07 | — | — | US | claimed |
| WO-1991018596-A1 | METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN | WEITZBERG MOSHE (US) | 1991-12-12 | — | — | WO | claimed |
| US-4960881-A | REACTING AMINO ACID WITH ALPHA-CHLORINATED CARBONATE IN SOLVENT IN PRESENCE OF ACID SCAVENGER | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1990-10-02 | — | — | US | claimed |
| EP-0303243-A2 | Use of atrial natriuretic factor (ANF), fragments and analogues thereof, for the treatment of cardiac disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-15 | — | — | EP | claimed |
| EP-0299397-A2 | Peptides with vasorelaxing, natriuretic and diuretic activities, preparation process, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | EGLN1 1806/4885PHF8 2786/4885KDM2A 3040/4885 |
| US-20230312653-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | EGLN1 2774/4885PHF8 4189/4885KDM2A 4825/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | EGLN1 1806/4885PHF8 2786/4885KDM2A 3040/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | EGLN1 1749/4885PHF8 3874/4885KDM2A 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.